Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,392 total articles

Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure

Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure

Callan JMB Inc. announced the development of Atlas Complex, a 150-acre pharmaceutical, medical, and logistics campus in Marion, Alabama. The facility will support pharmaceutical onshoring, early-stage production, QA/QC, cold-chain logistics, and domestic distribution. Partnering with Monarch Property Management and Walker's Pharmaceuticals of India…

Fusion Fuel Highlights Announced Exploration Plan at Jaguar Uranium’s Huemul Project, Potential Royalty Portfolio Income

Fusion Fuel Highlights Announced Exploration Plan at Jaguar Uranium’s Huemul Project, Potential Royalty Portfolio Income

Fusion Fuel Green PLC announced its planned acquisition of a controlling interest in Royal Uranium Inc., which holds a 1.0% NSR royalty on the Huemul Project in Argentina. This strategic move provides Fusion Fuel capital-efficient exposure to uranium, copper, and vanadium resources at a historically significant mining district. Jaguar Uranium's exp…

MainStreet Bancshares, Inc. Announces First Quarter 2026 Results

MainStreet Bancshares, Inc. Announces First Quarter 2026 Results

MainStreet Bancshares, Inc. reported a net income of $4.1 million for Q1 2026, with EPS of $0.48, driven by a 9 basis point expansion in net interest margin to 3.47%. The company executed a buyback of over 273,000 shares, strengthened its capital position, increased net loans to $1.85 billion, and maintained a strong 98% loan-to-deposit ratio. Depo…

Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve

Axe Compute Unveils Compute Reserve Dashboard, Giving Investors a Unified View of Its NASDAQ Stock and Operational Strategic Compute Reserve

Axe Compute Inc., a NASDAQ-listed AI infrastructure platform, announced the launch of its Strategic Compute Reserve (SCR) Dashboard. The dashboard consolidates detailed, real-time insights into the company's GPU asset reserves and stock metrics, improving transparency by integrating the equity valuation with the value and unlock schedule of its AI …

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics presented new compelling data demonstrating the effectiveness of its RedTail virotherapy platform, which systemically delivers targeted genetic medicines for cancer treatment. The company highlighted its lead candidate CLD-401 and introduced CLD-501 targeting TROP2, aiming to improve T-cell engagers' efficacy in solid tumors …

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Therapeutics reported positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial evaluating mivocabtagene autoleucel (miv-cel), a CAR T therapy, in patients with generalized myasthenia gravis (gMG). The data demonstrate rapid, robust, and sustained clinical improvements through 52 weeks after a single dose, with all pa…

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

BioCardia announced a favorable outcome from its clinical consultation with Japan's PMDA for CardiAMP Cell Therapy, signaling likely sufficiency of its clinical data to support regulatory approval for ischemic heart failure treatment in Japan. The company is positioned to become the first to offer a minimally invasive biologic therapy for this cond…

Cycurion CEO Kevin Kelly Discusses Operational Execution, Multi‑Year Contract Momentum, and 2026 Growth Priorities in Recent Interview

Cycurion CEO Kevin Kelly Discusses Operational Execution, Multi‑Year Contract Momentum, and 2026 Growth Priorities in Recent Interview

Cycurion, Inc. CEO Kevin Kelly discusses the company's strategic transition towards profitable growth through improved operational execution, cost-saving initiatives, and multi-year contract wins, including a significant government partnership. The company aims to grow revenues substantially in the coming years, overcoming prior challenges related …

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Biosciences announces publication of peer-reviewed research demonstrating the analgesic potential of its FABP5 inhibitor ART26.12 across multiple pain models, highlighting a differentiated mechanism with a favorable safety profile from Phase 1 studies. The company plans to initiate multiple ascending dose trials later this year to advance cl…

RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue

RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue

RedCloud Holdings plc is progressing its RAID AI engine from research to live integration within Turkey's leading distribution network, marking a major step towards commercial deployment. This move follows joint ventures in Turkey and Saudi Arabia, collectively valued up to $80 million, reflecting expansion in high-growth FMCG markets amid global s…

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Ltd. announced an updated corporate presentation emphasizing its strategic collaboration with Eledon Pharmaceuticals to develop a combined cell therapy and immune-protection approach targeting Type 1 Diabetes. The company's flagship program, NCEL-101, integrates stem-cell-derived islet replacement with Eledon's immune-modulation antibody te…

Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System

Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System

Nexera Technologies Ltd announced that its wholly-owned subsidiary, KeepZone AI Inc., has entered a white label agreement to develop and commercialize an advanced AI-powered real-time voice communication decision support system. This platform aims to enhance operational capabilities in managing multiple voice and radio communication channels simult…

Swvl Announces FY 2025 Results; Revenue Up 41% to $24.2 million; Net Income $1.3 million; NDR of 128%; GCC Revenue Up 122%

Swvl Announces FY 2025 Results; Revenue Up 41% to $24.2 million; Net Income $1.3 million; NDR of 128%; GCC Revenue Up 122%

Swvl Holdings Corp announced fiscal year 2025 financial results showing a 41% increase in revenue to $24.2 million and a net income of $1.3 million, marking a return to profitability after a $10.3 million loss in 2024. Revenue growth was driven by significant expansion in the Gulf Cooperation Council (GCC) region, with GCC revenues up 122%, alongsi…

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics announced that results from its Phase 3 SELVA and Phase 2 TOIVA clinical trials evaluating QTORIN™ 3.9% rapamycin anhydrous gel will be presented at the ISSVA World Congress 2026. These studies demonstrated statistically significant and clinically meaningful improvements in treating microcystic lymphatic malformations and cuta…

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell Therapeutics presented positive Phase 3 clinical data demonstrating preserved quality of life in heavily pretreated metastatic breast cancer patients receiving Bria-IMT combined with immune checkpoint inhibitors, alongside promising Phase 2 biomarker analyses at the 2026 AACR Annual Meeting. These findings support BriaCell's immunotherapy …

Dragonfly Energy Secures Multi-Million Dollar Order from Stevens Transport, Marking a Major Commercial Milestone

Dragonfly Energy Secures Multi-Million Dollar Order from Stevens Transport, Marking a Major Commercial Milestone

Dragonfly Energy announced a material purchase order valued at over $3 million from Stevens Transport for deployment across nearly 500 trucks throughout 2026. This order encompasses Dragonfly's full heavy-duty trucking product portfolio, including lithium-based solutions aimed at reducing engine idling, improving driver comfort, and lowering total …

New Found Gold Announces $205M Finance Package

New Found Gold Announces $205M Finance Package

New Found Gold Corp. announced a $205 million financing package consisting of a $100 million bought deal equity offering and a $105 million senior secured credit facility with EdgePoint. The funds will finance the initial capital expenditures for the Queensway Gold Project-Phase I, advancing it toward production, as well as general corporate purpos…

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic psychedelic therapeutics, announced positive top-line safety data from its ongoing FDA-approved Phase I/IIa trial of CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The drug met the primary safety and tolerability endpoint, showing a hig…